Brief: Petros Pharmaceuticals Says Unit Entered Into A Technology Transfer Service Agreement With Patheon Pharmaceuticals
24/01/2022 13:46
Jan 24 (Reuters) - Petros Pharmaceuticals Inc PTPI.O :
* PETROS PHARMACEUTICALS - ON JAN 20, UNIT ENTERED INTO A
TECHNOLOGY TRANSFER SERVICE AGREEMENT WITH PATHEON
PHARMACEUTICALS
* PETROS PHARMACEUTICALS - PARTIES TO COLLABORATE AS
PARTNERS FOR
COMMERCIAL PRODUCTION OF CO'S STENDRA (AVANAFIL) TABLETS AT
PATHEON’S FACILITIES
Source: (https://bit.ly/3KxupBn)
Further company coverage: PTPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Petros Pharmaceuticals
See all newsBrief: Petros Pharmaceuticals Assigns All Assets To Pt Liquidation, For Benefit Of Creditors
Brief: Petros Pharmaceuticals’ STENDRA Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Brief: Petros Pharmaceuticals Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Petros Pharmaceuticals Expands Online Distribution For Prescription STENDRA(R) Through New Agreement With Lemonaid Health
Brief: Petros Pharma Announces Partnership with Idea Evolver for Rx-to-OTC Switches & Digital Launch Solutions